TheraRadar
Data updated: May 26, 2026

METHAZOLAMIDE

Ophthalmology Approved 1993-06-30

METHAZOLAMIDE is indicated for the treatment of Glaucoma.

Source: FDA Label • BAUSCH AND LOMB INC
7
Indications
--
Phase 3 Trials
32
Years on Market

Details

Status
Prescription
First Approved
1993-06-30
Routes
ORAL
Dosage Forms
TABLET

METHAZOLAMIDE Approval History

1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
60 FDA actions from 1993 to 2026
Feb 2026 ORIGINAL
Update
Oct 2022 ORIGINAL
Update
Oct 2018 ORIGINAL
Update

What METHAZOLAMIDE Treats

1 indications

METHAZOLAMIDE is approved for 1 conditions since its original approval in 1993. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Glaucoma
Source: FDA Label

METHAZOLAMIDE Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Indication competitors

3

Same indication, different mechanism — what else might this patient receive?

Unlock 1 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to METHAZOLAMIDE

3 of 16

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ACETAZOLAMIDE
ACETAZOLAMIDE
1 shared
Sun Pharma
Shared indications:
ALPHAGAN P
BRIMONIDINE TARTRATE
1 shared
AbbVie
Shared indications:
BETAGAN
LEVOBUNOLOL HYDROCHLORIDE
1 shared
AbbVie
Shared indications:
📋

Clinical Trial Registry

7 trials
Trial Sponsor ID Phase Status Title
NCT02390284 STOP-RGCD results posted 20140587 R01EY014957 Ph 3 terminated Stop Retinal Ganglion Cell Dysfunction Study
NCT06312800 LeWitt02 Ph 2 withdrawn Acamprosate and Methazolamide for Essential Tremor
NCT02463357 results posted 15-0254 Ph 4 completed Three New Ideas to Protect Special Forces From the Stress of High Altitude
NCT02758470 H16-00896 Ph 4 completed Muscle Fatigue and Carbonic Anhydrase Inhibitors
NCT01587027 results posted GQ01 DARPA Ph 1 completed Safety Evaluation of Aminophylline and Methazolamide
NCT02760121 H16-00028 Ph 4 completed AZ, MZ, and the Pulmonary System Response to Hypoxia
NCT01702025 results posted N66001-10-C-2134 Ph 1, Ph 2 completed Rapid Acclimatization to Hypoxia at Altitude
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

METHAZOLAMIDE FDA Label Details

Indications & Usage

METHAZOLAMIDE is indicated for the treatment of Glaucoma.

Looking for the branded version?

NEPTAZANE

Full clinical data, patents, trials, and competitive landscape for methazolamide.

See NEPTAZANE

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.